|
Post by falconquest on Dec 31, 2018 17:44:53 GMT -5
Thanks for sharing perspectives. This is one conference call where I have no expectations or clue going in. I am anxious to hear Mike lay out plans for 2019 and his reasoning. The one puzzling thing to me is believing that Mike knew what would happen to the stock with the recent sell. He also knew that he had only recently stated no further dilution was expected in the near term. This leads me to think something new and interesting may be up. Whether it's good or bad is anyone's guess. I agree it will be bad if this is simply a rehash of what's already known. Well, there had better be something new and interesting up because we can all see what's coming. The dilution, (which caused a hit to the SP) then the request for additional shares (causing a further hit to share price) which leads us into Nasdaq non-compliance territory (shorts pile on) which once again leads to another reverse split. Mr. Castagna better have an ace in his pocket on Friday! It's not hard to read the tea leaves here.
|
|
|
Post by mnholdem on Dec 31, 2018 18:12:41 GMT -5
They couldn't even get the name of the call right in the NR: they meant to write: "MannKind to Hold Irate Investor Conference Call." I think you're correct baba. If management had announced a conference call immediately with the PR announcing the offering, it may have calmed things down a notch. By waiting, management gave the appearance that the CC was scheduled as an afterthought and only in response to shareholders getting angrier by the day.
|
|
|
Post by lennymnkd on Dec 31, 2018 18:22:22 GMT -5
Let's think positive! Maybe it has to do with the timing of a deal 😜
|
|
|
Post by winstonsmith on Dec 31, 2018 19:05:47 GMT -5
Mike should step down.....and the BOD is and has been worthless for a decade.
|
|
|
Post by sexychefski on Dec 31, 2018 19:06:28 GMT -5
It wasn't personal, just business.
|
|
|
Post by lifebreath on Dec 31, 2018 21:28:41 GMT -5
Mike should step down.....and the BOD is and has been worthless for a decade. Chris Viehbacher might be a good choice for ceo he shared Al’s vision
|
|
|
Post by longliner on Dec 31, 2018 22:37:36 GMT -5
Oh give it a rest!! Friday will be here before you know it, then you will have all year to squeal depending on the news and your position.
|
|
|
Post by slugworth008 on Jan 1, 2019 5:51:01 GMT -5
Only Mike will be presenting! I hope that this shelf offering of 26,666,667 common shares will turn out to be a 10% co-promotion partner buy-in I don't have that much hopium left. It has been beaten out of me - - and my broke-rage account.
|
|
|
Post by sportsrancho on Jan 1, 2019 7:44:16 GMT -5
To be clear I do not like what happened, the timing or the way this equity raise was put together, I do believe Mike is working around the clock to be successful, but I also believe that this is the bottom line as far as Wall Street goes. Net Afrezza revenue to Mannkind in 2018 will be around $18mm. For 2019, that number needs to triple (US sales) and if it doesn't, then the company needs to transition to an organization that focuses on developing TS deals. The current dual path of Afrezza and TS deals isn't cutting it and yes, I realize the challenges the company and Afrezza have faced but I have been patient and Wall Street quite frankly isn't going to respond any differently than it has in the past if there are not changes in 2019. Read more: mnkd.proboards.com/thread/10754/mannkind-corporation-hold-investor-conference?page=1#ixzz5bMKDYcxa
|
|
|
Post by sportsrancho on Jan 1, 2019 10:00:46 GMT -5
|
|
|
Post by sayhey24 on Jan 1, 2019 10:10:30 GMT -5
To be clear I do not like what happened, the timing or the way this equity raise was put together, I do believe Mike is working around the clock to be successful, but I also believe that this is the bottom line as far as Wall Street goes. Net Afrezza revenue to Mannkind in 2018 will be around $18mm. For 2019, that number needs to triple (US sales) and if it doesn't, then the company needs to transition to an organization that focuses on developing TS deals. The current dual path of Afrezza and TS deals isn't cutting it and yes, I realize the challenges the company and Afrezza have faced but I have been patient and Wall Street quite frankly isn't going to respond any differently than it has in the past if there are not changes in 2019. Read more: mnkd.proboards.com/thread/10754/mannkind-corporation-hold-investor-conference?page=1#ixzz5bMKDYcxaThere are two questions with regard to afrezza going into 2019.
The first is what affect will the limited SOC changes have to T1 sales? Maybe this past weeks numbers are a positive indicator. If so 3X 2018 sales seems doable and then MNKD is getting close to break even.
The second is what does Dr. Kendall have planned for ADA2019? Will we see anything regarding the T2s? A lesson from 2018 is that changes can be made to the SOCs if data is presented at the ADA meeting.
|
|
|
Post by morfu on Jan 1, 2019 11:02:50 GMT -5
To be clear I do not like what happened, the timing or the way this equity raise was put together, I do believe Mike is working around the clock to be successful, but I also believe that this is the bottom line as far as Wall Street goes. Net Afrezza revenue to Mannkind in 2018 will be around $18mm. For 2019, that number needs to triple (US sales) and if it doesn't, then the company needs to transition to an organization that focuses on developing TS deals. The current dual path of Afrezza and TS deals isn't cutting it and yes, I realize the challenges the company and Afrezza have faced but I have been patient and Wall Street quite frankly isn't going to respond any differently than it has in the past if there are not changes in 2019. Read more: mnkd.proboards.com/thread/10754/mannkind-corporation-hold-investor-conference?page=1#ixzz5bMKDYcxaThere are two questions with regard to afrezza going into 2019.
The first is what affect will the limited SOC changes have to T1 sales? Maybe this past weeks numbers are a positive indicator. If so 3X 2018 sales seems doable and then MNKD is getting close to break even.
The second is what does Dr. Kendall have planned for ADA2019? Will we see anything regarding the T2s? A lesson from 2018 is that changes can be made to the SOCs if data is presented at the ADA meeting.
Why setting overambitious goals!? In the last two years we doubled per year, maybe a bit more! I would be perfectly happy if another double could be done this year! Green numbers in 2020! However, I don't understand why the stock market is not catching up on that trend.. the potential value here seems obvious
Hopefully, it will be the biggest miracle of my life as to why that certain day was picked to make Mannkind a billion$ company again..
|
|
|
Post by goyocafe on Jan 1, 2019 11:16:19 GMT -5
To be clear I do not like what happened, the timing or the way this equity raise was put together, I do believe Mike is working around the clock to be successful, but I also believe that this is the bottom line as far as Wall Street goes. Net Afrezza revenue to Mannkind in 2018 will be around $18mm. For 2019, that number needs to triple (US sales) and if it doesn't, then the company needs to transition to an organization that focuses on developing TS deals. The current dual path of Afrezza and TS deals isn't cutting it and yes, I realize the challenges the company and Afrezza have faced but I have been patient and Wall Street quite frankly isn't going to respond any differently than it has in the past if there are not changes in 2019. Read more: mnkd.proboards.com/thread/10754/mannkind-corporation-hold-investor-conference?page=1#ixzz5bMKDYcxaThere are two questions with regard to afrezza going into 2019.
The first is what affect will the limited SOC changes have to T1 sales? Maybe this past weeks numbers are a positive indicator. If so 3X 2018 sales seems doable and then MNKD is getting close to break even.
The second is what does Dr. Kendall have planned for ADA2019? Will we see anything regarding the T2s? A lesson from 2018 is that changes can be made to the SOCs if data is presented at the ADA meeting.
I think it’s important to know exactly what data the ADA wants that it doesn’t already have with regard to Afrezza. The FDA has already indicated that it is equally efficacious as injectable insulin, so why the resistance to list it along side its injectable counterparts in the recommended protocol? Awareness would climb significantly with that recommendation as much as reluctance to prescribe it would decline. we don’t need Afrezza to replace the recommendation for injectable mealtime insulin to gain market share, but as long as the ADA lists it below bariatric surgery in the document, it will continue to be viewed as a secondary, inferior option. I think MNKD knows why the ADA won’t list Afrezza as an equal. I would like them to state it publicly for the record.
|
|
|
Post by prcgorman2 on Jan 1, 2019 12:31:23 GMT -5
Mike should step down.....and the BOD is and has been worthless for a decade. Wow. Thank you for that deeply insightful and very helpful analysis and observation. Take a look at the Afrezza sales chart that posts every week. Do the math on the percentage increase in sales since January 2017. Take a look at the revenue as compared to when Sanofi was selling Afrezza (with supposedly 500 salespeople or approximately 5X the quantity working for Mannkind Corp now). Take a look at how long it took to go from the range of 400 Rx a week to 500, and then 500 to 600, and then 600 to 700. What you will see is a pattern of acceleration and it does not seem unreasonable to anticipate it will continue. In fact the numbers indicate better than linear performance. It's too early to say it is the upswing in the long awaited "hockey stick". We'll need to see if 1Q or at least 2019 can maintain the momentum. It is noteworthy that Mannkind salesforce is acheiving new sales records for new prescriptions, not just refills. If the sales growth was only linear it would still indicate likely profitability on sales of Afrezza in the next 2 to 3 years. That is not what we're hoping for, but I've worked in an industry where profitability takes a long time (3 to 5 years) to achieve so the current progress doesn't bother me a bit. It's definitely material and moving in the right direction. I feel like Dr. Castagna inherited a gem in the rough and he's worked harder than most CEOs do to polish it and make it recognized for the value I believe it has. Step down? I'd be OK with Ken Kresa stepping down at some point (no hurry for that either) and letting Mike hold that role too. I think we lucked out and got a rock star and if you can't see that, well, I'm not very interested in reading any more of your posts or the posts of any of the other low count no count posters either. For those who think I'm blind to impacts on stock price or mindful management of the source and costs of capital, I'll politely disagree and merely say that I prefer to let things develop some before coming to any conclusions about good choices or missteps.
|
|
|
Post by agedhippie on Jan 1, 2019 13:13:27 GMT -5
Mike should step down.....and the BOD is and has been worthless for a decade. ... Step down? I'd be OK with Ken Kresa stepping down at some point (no hurry for that either) and letting Mike hold that role too. I think we lucked out and got a rock star and if you can't see that, well, I'm not very interested in reading any more of your posts or the posts of any of the other low count no count posters either. I think that would be a very bad move. This is Mike's first time as a CEO and he needs someone like Ken Kresa who has experience guiding him. Mike is doing well, but he is learning on the job, he has never been in this sort of position before.
|
|